Terms: = Lung cancer AND MUC16, CA125, CA-125
522 results:
1. Clinical effect of anlotinib in combination with docetaxel in treating advanced non-small cell lung cancer.
Weng G; Fang W; Lin Y; Chen L; Su W
Cell Mol Biol (Noisy-le-grand); 2024 Apr; 70(4):212-216. PubMed ID: 38678603
[TBL] [Abstract] [Full Text] [Related]
2. Determination of Tumor Marker Screening for lung cancer Using ROC Curves.
Dou X; Lu J; Yu Y; Yi Y; Zhou L
Dis Markers; 2024; 2024():4782618. PubMed ID: 38549716
[TBL] [Abstract] [Full Text] [Related]
3. Standardized uptake value
Jin B; Wen X; Tian H; Guo H; Hao M; Wu J; Li X; Ren Y; Wang X; Ren X
Cancer Med; 2024 Apr; 13(7):e6961. PubMed ID: 38549459
[TBL] [Abstract] [Full Text] [Related]
4. Factors influencing blood tumor marker concentrations in the absence of neoplasia.
Trapé J; Fernández-Galán E; Auge JM; Carbonell-Prat M; Filella X; Miró-Cañís S; González-Fernández C;
Tumour Biol; 2024; 46(s1):S35-S63. PubMed ID: 38517826
[TBL] [Abstract] [Full Text] [Related]
5. Humoral immune response to tumor-associated antigen Ubiquilin 1 (UBQLN1) and its tumor-promoting potential in lung cancer.
Wang Y; Ouyang S; Liu M; Si Q; Zhang X; Zhang X; Li J; Wang P; Ye H; Shi J; Song C; Wang K; Dai L
BMC Cancer; 2024 Mar; 24(1):283. PubMed ID: 38431566
[TBL] [Abstract] [Full Text] [Related]
6. Relevance of tumor markers for prognosis and predicting therapy response in non-small cell lung cancer patients: A CEPAC-TDM biomarker substudy.
Geiger K; Joerger M; Roessler M; Hettwer K; Ritter C; Simon K; Uhlig S; Holdenrieder S
Tumour Biol; 2024; 46(s1):S191-S206. PubMed ID: 38363625
[TBL] [Abstract] [Full Text] [Related]
7. Diagnostic value of cerebrospinal fluid human epididymis protein 4 for leptomeningeal metastasis in lung adenocarcinoma.
Li X; Chen K; Li J; Tang X; Ruan H; Guan M
Front Immunol; 2024; 15():1339914. PubMed ID: 38304432
[TBL] [Abstract] [Full Text] [Related]
8. The role of adenocarcinoma subtypes and immunohistochemistry in predicting lymph node metastasis in early invasive lung adenocarcinoma.
Xue M; Liu J; Li Z; Lu M; Zhang H; Liu W; Tian H
BMC Cancer; 2024 Jan; 24(1):139. PubMed ID: 38287300
[TBL] [Abstract] [Full Text] [Related]
9. Improvement of differential diagnosis of lung cancer by use of multiple protein tumor marker combinations.
Trulson I; Klawonn F; von Pawel J; Holdenrieder S
Tumour Biol; 2024; 46(s1):S81-S98. PubMed ID: 38277317
[TBL] [Abstract] [Full Text] [Related]
10. Risk factors and prognosis of malignant peritoneal mesothelioma with paraneoplastic syndrome.
Liang XL; Su YD; Li XB; Fu YB; Ma R; Yang R; Wu HL; Li Y
World J Surg Oncol; 2024 Jan; 22(1):29. PubMed ID: 38267958
[TBL] [Abstract] [Full Text] [Related]
11. IR808@MnO nano-near infrared fluorescent dye's diagnostic value for malignant pleural effusion.
Wang X; Yan X; Zhang Z; Xu C; Du F; Xie Y; Yin X; Lei Z; Jiang Y; Yang W; Zhou X; Wang Y
Respir Res; 2024 Jan; 25(1):22. PubMed ID: 38195540
[TBL] [Abstract] [Full Text] [Related]
12. Screening of novel tumor-associated antigens for lung adenocarcinoma mRNA vaccine development based on pyroptosis phenotype genes.
Zhou F; Wang M; Wang Z; Li W; Lu X
BMC Cancer; 2024 Jan; 24(1):28. PubMed ID: 38166691
[TBL] [Abstract] [Full Text] [Related]
13. Integrative Multianalytical Model Based on Novel Plasma Protein Biomarkers for Distinguishing lung Adenocarcinoma and Benign Pulmonary Nodules.
Zhang X; Ji L; Liu M; Li J; Sun H; Liang F; Zhao Y; Wang Z; Yang T; Wang Y; Si Q; Du R; Dai L; Ouyang S
J Proteome Res; 2024 Jan; 23(1):277-288. PubMed ID: 38085828
[TBL] [Abstract] [Full Text] [Related]
14. Identification of hypoxia-related gene signatures based on multi-omics analysis in lung adenocarcinoma.
Luo Q; Li X; Meng Z; Rong H; Li Y; Zhao G; Zhu H; Cen L; Liao Q
J Cell Mol Med; 2024 Jan; 28(2):e18032. PubMed ID: 38013642
[TBL] [Abstract] [Full Text] [Related]
15. [Diagnostic values of conventional tumor markers and their combination with chest CT for patients with stageⅠA lung cancer].
Peng Q; Wu N; Huang Y; Zhao SJ; Tang W; Liang M; Ran YL; Xiao T; Yang L; Liang X
Zhonghua Zhong Liu Za Zhi; 2023 Nov; 45(11):934-941. PubMed ID: 37968078
[No Abstract] [Full Text] [Related]
16. Predictive value of
Zhang Q; Tao X; Yuan P; Zhang Z; Ying J; Guo L; Li N; Wang S; Li J; Liu Y; Guo W; Zhao S; Wu N
Cancer Med; 2023 Nov; 12(22):20864-20877. PubMed ID: 37965789
[TBL] [Abstract] [Full Text] [Related]
17. Comprehensive characterization of muc16 mutations in lung adenocarcinoma for immunotherapies and prognosis: An observational study.
Liu T; Wu L; Liu J; Chen H; Zhu B; Qiao D; Zhu Y; Liu T; Chen Q; Hu A
Medicine (Baltimore); 2023 Nov; 102(44):e35481. PubMed ID: 37932988
[TBL] [Abstract] [Full Text] [Related]
18. Prognostic value of blood-based protein biomarkers in non-small cell lung cancer: A critical review and 2008-2022 update.
Trulson I; Holdenrieder S
Tumour Biol; 2024; 46(s1):S111-S161. PubMed ID: 37927288
[TBL] [Abstract] [Full Text] [Related]
19. CYFRA 21-1, CA 125 and CEA provide additional prognostic value in NSCLC patients with stable disease at first CT scan.
Muley T; Schneider MA; Meister M; Thomas M; Heußel CP; Kriegsmann M; Holdenrieder S; Wehnl B; Rolny V; Mang A; Gerber R; Herth F
Tumour Biol; 2024; 46(s1):S163-S175. PubMed ID: 37840516
[TBL] [Abstract] [Full Text] [Related]
20. Macrophage migration inhibitory factor may contribute to the occurrence of multiple primary lung adenocarcinomas.
Liu W; Yang HS; Zhi FH; Feng YF; Luo HH; Zhu Y; Lei YY
Clin Transl Med; 2023 Oct; 13(10):e1368. PubMed ID: 37784249
[TBL] [Abstract] [Full Text] [Related]
[Next]
